Compare
Labcorp Holdings Inc. vs Quest Diagnostics Inc vs Fortrea Holdings Inc. vs Natera, Inc.
| Latest fiscal year | Labcorp Holdings Inc. LH | Quest Diagnostics Inc DGX | Fortrea Holdings Inc. FTRE | Natera, Inc. NTRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.95B | $11.04B | $2.72B | $2.31B |
| Revenue growth (YoY) | +7.2% | +11.8% | +1.0% | +35.9% |
| Gross margin | 28.8% | 33.2% (computed) | n/a | n/a |
| Operating margin | 9.9% | 14.1% | -32.0% | -13.4% |
| Net margin | 6.3% | 9.0% | -36.2% | -9.0% |
| Net income | $876.50M | $992.00M | -$986.20M | -$208.16M |
| EPS (Diluted) | $10.46 | $8.75 | -$10.81 | -$1.52 |
| Operating cash flow | $1.64B | $1.89B | $113.50M | $215.30M |
| Free cash flow | $1.21B | $1.36B | $88.30M | $109.11M |
| Cash & equivalents | $532.30M | $420.00M | $174.60M | n/a |
| Total assets | $18.39B | $16.23B | $2.72B | $2.40B |
| Total liabilities | $9.76B | n/a | $2.15B | $685.93M |
| Shareholders' equity | $8.62B | $7.21B | $563.50M | $1.71B |
| Return on year-end equity | 10.2% | 13.8% | -175.0% | -12.2% |
| Shares outstanding | 82.20M | n/a | 93.10M | 139.69M |
Revenue, most recent five fiscal years
| Fiscal year | Labcorp Holdings Inc. | Quest Diagnostics Inc | Fortrea Holdings Inc. | Natera, Inc. |
|---|---|---|---|---|
| Latest | $13.95B Ended 2025-12-31 | $11.04B Ended 2025-12-31 | $2.72B Ended 2025-12-31 | $2.31B Ended 2025-12-31 |
| 1 year earlier | $13.01B Ended 2024-12-31 | $9.87B Ended 2024-12-31 | $2.70B Ended 2024-12-31 | $1.70B Ended 2024-12-31 |
| 2 years earlier | $12.16B Ended 2023-12-31 | $9.25B Ended 2023-12-31 | $2.84B Ended 2023-12-31 | $1.08B Ended 2023-12-31 |
| 3 years earlier | $11.86B Ended 2022-12-31 | $9.88B Ended 2022-12-31 | $2.84B Ended 2022-12-31 | $820.22M Ended 2022-12-31 |
| 4 years earlier | $13.14B Ended 2021-12-31 | $10.79B Ended 2021-12-31 | $3.06B Ended 2021-12-31 | $625.49M Ended 2021-12-31 |